Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2026-09-02 16:30:31 ET · period of report 2026-08-31 · accession 0000905148-26-004065 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-02 16:30 | 2026-08-31 | ACRV | Levin Michaela | Chief Business Off | A - Grant | $0.00 | +30.0K | 30.0K | New | $0 |
| D | 2026-09-02 16:30 | 2026-08-31 | ACRV | Levin Michaela | Chief Business Off | A - Grant | $0.00 | +130.0K | 130.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-31 | A | A | 30,000 | $0.00 | 30,000 | D | — | — | (F1) These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on September 1, 2027, subject to the Reporting Person's continuous service through such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-08-31 | A | A | 130,000 | $0.00 | 130,000 | D | $2.09 · — to 2036-08-30 | 130,000 Common Stock | (F2) Twenty-five percent (25%) of the shares subject to the option vest on September 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. |